Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer - PubMed
3 hours ago
- #PARP inhibitors
- #mCRPC
- #genomic biomarkers
- PARP inhibitors (PARPis) are effective for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations.
- The study analyzed 120 mCRPC patients treated with PARPis, finding 54% had BRCA2/1 alterations and 16% had no HRR gene alterations.
- Response rates were 37% for PSA50 and 43% for RECIST, with BRCA2 alterations showing the highest response rates (52% PSA50, 72% RECIST).
- Biallelic BRCA2 loss was associated with better outcomes, and mutational signatures were linked to BRCA-mutated status and PARPi response.
- Some responders lacked known HRR gene alterations, suggesting the need for broader genomic biomarkers.
- The study supports HRR gene testing for PARPi use in mCRPC but highlights limitations like small size and retrospective design.